| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Alternative Treatments for Myelodysplastic Syndromes
|
Sekeres, Mikkael
|
|
2005
|
|
S2 |
p. S32-S37
6 p.
|
artikel
|
| 2 |
Arsenic and Old Lace: Novel Approaches in Elderly Patients With Acute Myeloid Leukemia
|
Roboz, Gail J.
|
|
2008
|
|
S2 |
p. S22-S24
3 p.
|
artikel
|
| 3 |
Atypical Chronic Myeloproliferative Disorders: Genes and Imatinib-Sensitive Targets
|
Martinelli, Giovanni
|
|
2007
|
|
S2 |
p. S1-S3
3 p.
|
artikel
|
| 4 |
Bendamustine in Chronic Lymphocytic Leukemia and Refractory Lymphoma
|
Rummel, Mathias J.
|
|
2008
|
|
S2 |
p. S7-S10
4 p.
|
artikel
|
| 5 |
Chronic myeloid disorders: Classification and treatment overview
|
Tefferi, Ayalew
|
|
2001
|
|
S2 |
p. 1-4
4 p.
|
artikel
|
| 6 |
Chronic myeloid leukemia in the imatinib era
|
Druker, Brian J.
|
|
2003
|
|
S2 |
p. 1-3
3 p.
|
artikel
|
| 7 |
Clinical decisions for chronic myeloid leukemia in the imatinib era
|
Goldman, John M.
|
|
2003
|
|
S2 |
p. 98-103
6 p.
|
artikel
|
| 8 |
CME test
|
|
|
2000
|
|
S2 |
p. 51-54
4 p.
|
artikel
|
| 9 |
Comments on the Hammersmith policy
|
Cortes, Jorge
|
|
2003
|
|
S2 |
p. 105-106
2 p.
|
artikel
|
| 10 |
Comments on the Hammersmith policy
|
Daley, George Q.
|
|
2003
|
|
S2 |
p. 106-
1 p.
|
artikel
|
| 11 |
Comments on the Hammersmith policy
|
Baccarani, Michele
|
|
2003
|
|
S2 |
p. 104-
1 p.
|
artikel
|
| 12 |
Comments on the Hammersmith policy
|
Guilhot, François
|
|
2003
|
|
S2 |
p. 108-109
2 p.
|
artikel
|
| 13 |
Comments on the Hammersmith policy
|
Hughes, Tim
|
|
2003
|
|
S2 |
p. 111-112
2 p.
|
artikel
|
| 14 |
Comments on the Hammersmith policy
|
Hochhaus, Andreas
|
|
2003
|
|
S2 |
p. 109-110
2 p.
|
artikel
|
| 15 |
Comments on the Hammersmith policy
|
Mahon, Francois-Xavier
|
|
2003
|
|
S2 |
p. 112-113
2 p.
|
artikel
|
| 16 |
Comments on the Hammersmith policy
|
Druker, Brian J.
|
|
2003
|
|
S2 |
p. 107-108
2 p.
|
artikel
|
| 17 |
Current management in polycythemia vera
|
Gilbert, Harriet S
|
|
2001
|
|
S2 |
p. 25-28
4 p.
|
artikel
|
| 18 |
Cytogenetic and molecular mechanisms of resistance to imatinib
|
Hochhaus, Andreas
|
|
2003
|
|
S2 |
p. 69-79
11 p.
|
artikel
|
| 19 |
Cytogenetic studies in patients on imatinib
|
Deininger, Michael W.N.
|
|
2003
|
|
S2 |
p. 50-55
6 p.
|
artikel
|
| 20 |
Decitabine Dosing Schedules
|
Kantarjian, Hagop M.
|
|
2005
|
|
S2 |
p. S17-S22
6 p.
|
artikel
|
| 21 |
Decitabine in Acute Myeloid Leukemia
|
Lübbert, Michael
|
|
2005
|
|
S2 |
p. S38-S42
5 p.
|
artikel
|
| 22 |
Decitabine in Chronic Leukemias
|
Issa, Jean-Pierre J.
|
|
2005
|
|
S2 |
p. S43-S49
7 p.
|
artikel
|
| 23 |
Decitabine in Myelodysplastic Syndromes
|
Saba, Hussain I.
|
|
2005
|
|
S2 |
p. S23-S31
9 p.
|
artikel
|
| 24 |
Emerging Role of Epigenetic Therapy: Focus on Decitabine
|
Issa, Jean-Pierre J.
|
|
2005
|
|
S2 |
p. S1-S2
2 p.
|
artikel
|
| 25 |
Evaluation of diagnostic criteria in polycythemia vera
|
Pearson, Thomas C
|
|
2001
|
|
S2 |
p. 21-24
4 p.
|
artikel
|
| 26 |
Ex vivo manipulation of hematopoietic stem and progenitor cells
|
Brugger, Wolfram
|
|
2000
|
|
S2 |
p. 42-49
8 p.
|
artikel
|
| 27 |
Future Directions for the Use of Hypomethylating Agents
|
Garcia-Manero, Guillermo
|
|
2005
|
|
S2 |
p. S50-S59
10 p.
|
artikel
|
| 28 |
Hemophilia therapy innovation: development of an advanced category recombinant factor VIII by a plasma/albumin-free method
|
|
|
2004
|
|
S2 |
p. A2-
1 p.
|
artikel
|
| 29 |
Hemophilia therapy innovation: development of an advanced category recombinant factor VIII by a plasma/albumin-free method
|
Ewenstein, B.M
|
|
2004
|
|
S2 |
p. 1-16
16 p.
|
artikel
|
| 30 |
Hypereosinophilic Syndrome and Molecularly Targeted Therapy
|
Martinelli, Giovanni
|
|
2007
|
|
S2 |
p. S4-S16
13 p.
|
artikel
|
| 31 |
Imatinib: A targeted clinical drug development
|
Capdeville, Renaud
|
|
2003
|
|
S2 |
p. 15-20
6 p.
|
artikel
|
| 32 |
Imatinib in combination with cytarabine for the treatment of Philadelphia-positive chronic myelogenous leukemia chronic-phase patients: Rationale and design of phase I/II trials
|
Guilhot, François
|
|
2003
|
|
S2 |
p. 92-97
6 p.
|
artikel
|
| 33 |
Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia
|
O'Brien, Stephen G.
|
|
2003
|
|
S2 |
p. 26-30
5 p.
|
artikel
|
| 34 |
Imatinib mesylate in combination with other chemotherapeutic drugs: In vitro studies
|
Tipping, Alex J.
|
|
2003
|
|
S2 |
p. 83-91
9 p.
|
artikel
|
| 35 |
Imatinib treatment: Specific issues related to safety, fertility, and pregnancy
|
Hensley, Martee L.
|
|
2003
|
|
S2 |
p. 21-25
5 p.
|
artikel
|
| 36 |
Innovations in allogeneic stem-cell transplantation
|
DiPersio, John F
|
|
2000
|
|
S2 |
p. 33-41
9 p.
|
artikel
|
| 37 |
Introduction: Evolution of Targeted and Multifunctional Agents for Leukemias and Lymphomas
|
Tallman, Martin S.
|
|
2008
|
|
S2 |
p. S1-
1 p.
|
artikel
|
| 38 |
Introduction: The biologic basis of stem-cell therapy
|
DiPersio, John F
|
|
2000
|
|
S2 |
p. 1-2
2 p.
|
artikel
|
| 39 |
Management of Chemotherapy-Induced Thrombocytopenia: Current Status of Thrombopoietic Agents
|
Vadhan-Raj, Saroj
|
|
2009
|
|
S2 |
p. S26-S32
7 p.
|
artikel
|
| 40 |
Masthead
|
|
|
2006
|
|
S2 |
p. CO2-
1 p.
|
artikel
|
| 41 |
Masthead
|
|
|
2007
|
|
S2 |
p. IFC-
1 p.
|
artikel
|
| 42 |
Masthead
|
|
|
2005
|
|
S2 |
p. CO2-
1 p.
|
artikel
|
| 43 |
Masthead
|
|
|
2004
|
|
S2 |
p. C2-
1 p.
|
artikel
|
| 44 |
Mechanisms of granulocyte colony-stimulating factor-induced hematopoietic progenitor-cell mobilization
|
Link, Daniel C
|
|
2000
|
|
S2 |
p. 25-32
8 p.
|
artikel
|
| 45 |
Mechanisms of stem-/progenitor-cell mobilization: The anti-VLA-4 paradigm
|
Papayannopoulou, Thalia
|
|
2000
|
|
S2 |
p. 11-18
8 p.
|
artikel
|
| 46 |
Molecular mechanisms of transformation by the BCR-ABL oncogene
|
Sattlermc, Martin
|
|
2003
|
|
S2 |
p. 4-10
7 p.
|
artikel
|
| 47 |
Molecular monitoring of chronic myeloid leukemia
|
Hughes, Tim
|
|
2003
|
|
S2 |
p. 62-68
7 p.
|
artikel
|
| 48 |
Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment
|
Roche-Lestienne, Catherine
|
|
2003
|
|
S2 |
p. 80-82
3 p.
|
artikel
|
| 49 |
Overview of Cancer Epigenetics
|
Jones, Peter A.
|
|
2005
|
|
S2 |
p. S3-S8
6 p.
|
artikel
|
| 50 |
Paradigm shifts in stem-cell biology
|
Spangrude, Gerald J
|
|
2000
|
|
S2 |
p. 3-10
8 p.
|
artikel
|
| 51 |
Pathobiology of Secondary Immune Thrombocytopenia
|
Cines, Douglas B.
|
|
2009
|
|
S2 |
p. S2-S14
13 p.
|
artikel
|
| 52 |
Pathogenetic mechanisms of polycythemia vera and congenital polycythemic disorders
|
Prchal, Josef T
|
|
2001
|
|
S2 |
p. 10-20
11 p.
|
artikel
|
| 53 |
Pentostatin for the Treatment of Indolent Lymphoproliferative Disorders
|
Ho, Anthony D.
|
|
2006
|
|
S2 |
p. S2-S10
9 p.
|
artikel
|
| 54 |
Pharmacology of 5-Aza-2′-deoxycytidine (decitabine)
|
Momparler, Richard L.
|
|
2005
|
|
S2 |
p. S9-S16
8 p.
|
artikel
|
| 55 |
Physiology of myeloproliferation
|
Solberg Jr, Lawrence A
|
|
2001
|
|
S2 |
p. 5-9
5 p.
|
artikel
|
| 56 |
Prediction of response to imatinib by cDNA microarray analysis
|
Ohno, Ryuzo
|
|
2003
|
|
S2 |
p. 42-49
8 p.
|
artikel
|
| 57 |
Proceedings of the Washington University School of Medicine Symposium “The Biologic Basis of Stem-Cell Therapy”
|
|
|
2000
|
|
S2 |
p. 55-
1 p.
|
artikel
|
| 58 |
Purine Analogue-Based Chemotherapy Regimens for Patients With Previously Untreated B-Chronic Lymphocytic Leukemia
|
Kay, Neil E.
|
|
2006
|
|
S2 |
p. S50-S54
5 p.
|
artikel
|
| 59 |
Purine Analogue-Based Chemotherapy Regimens for Second-Line Therapy in Patients With Chronic Lymphocytic Leukemia
|
Lamanna, Nicole
|
|
2006
|
|
S2 |
p. S44-S49
6 p.
|
artikel
|
| 60 |
Purine Analogue Combinations for Indolent Lymphomas
|
Di Bella, Nicholas
|
|
2006
|
|
S2 |
p. S11-S21
11 p.
|
artikel
|
| 61 |
Purine Analogues in Advanced T-Cell Lymphoid Malignancies
|
Kurzrock, Razelle
|
|
2006
|
|
S2 |
p. S27-S34
8 p.
|
artikel
|
| 62 |
Purine Analogues in the Treatment of Lymphoid Malignancies
|
Foss, Francine
|
|
2006
|
|
S2 |
p. S1-
1 p.
|
artikel
|
| 63 |
Quality of life on imatinib
|
Hahn, Elizabeth A.
|
|
2003
|
|
S2 |
p. 31-36
6 p.
|
artikel
|
| 64 |
Questions and answers
|
|
|
2004
|
|
S2 |
p. 16-18
3 p.
|
artikel
|
| 65 |
Recognizing and Treating Secondary Immune Thrombocytopenic Purpura Associated With Lymphoproliferative Disorders
|
Liebman, Howard A.
|
|
2009
|
|
S2 |
p. S33-S36
4 p.
|
artikel
|
| 66 |
Role of Imatinib-Sensitive Tyrosine Kinases in the Pathogenesis of Chronic Myeloproliferative Disorders
|
DeAngelo, Daniel J.
|
|
2007
|
|
S2 |
p. S17-S30
14 p.
|
artikel
|
| 67 |
Role of Single-Agent Purine Analogues in Therapy of Peripheral T-Cell Lymphomas
|
Dearden, Claire E.
|
|
2006
|
|
S2 |
p. S22-S26
5 p.
|
artikel
|
| 68 |
Supplement Disclaimer
|
|
|
2008
|
|
S2 |
p. A2-
1 p.
|
artikel
|
| 69 |
Supplement disclaimer
|
|
|
2006
|
|
S2 |
p. A2-
1 p.
|
artikel
|
| 70 |
Supplement Disclaimer
|
|
|
2007
|
|
S2 |
p. A2-
1 p.
|
artikel
|
| 71 |
Supplement Disclaimer
|
|
|
2009
|
|
S2 |
p. A2-
1 p.
|
artikel
|
| 72 |
Supplement disclaimer
|
|
|
2005
|
|
S2 |
p. A2-
1 p.
|
artikel
|
| 73 |
Suppl Masthead
|
|
|
2008
|
|
S2 |
p. IFC-
1 p.
|
artikel
|
| 74 |
Suppl Masthead
|
|
|
2009
|
|
S2 |
p. IFC-
1 p.
|
artikel
|
| 75 |
Suppl TOC
|
|
|
2008
|
|
S2 |
p. A1-
1 p.
|
artikel
|
| 76 |
Table of contents
|
|
|
2006
|
|
S2 |
p. A1-
1 p.
|
artikel
|
| 77 |
Table of Contents
|
|
|
2007
|
|
S2 |
p. A1-
1 p.
|
artikel
|
| 78 |
Table of Contents
|
|
|
2009
|
|
S2 |
p. A1-
1 p.
|
artikel
|
| 79 |
Table of contents
|
|
|
2005
|
|
S2 |
p. A1-
1 p.
|
artikel
|
| 80 |
Table of contents
|
|
|
2004
|
|
S2 |
p. A1-
1 p.
|
artikel
|
| 81 |
Targeted Treatment and New Agents in Diffuse Large B-Cell Lymphoma
|
Leonard, John P.
|
|
2008
|
|
S2 |
p. S11-S16
6 p.
|
artikel
|
| 82 |
Targeting FLT3 for the Treatment of Leukemia
|
Small, Donald
|
|
2008
|
|
S2 |
p. S17-S21
5 p.
|
artikel
|
| 83 |
The Changing Landscape of Secondary ITP
|
|
|
2009
|
|
S2 |
p. S59-S60
2 p.
|
artikel
|
| 84 |
The Changing Landscape of Secondary ITP
|
|
|
2009
|
|
S2 |
p. A3-A5
nvt p.
|
artikel
|
| 85 |
The Changing Landscape of Secondary ITP
|
|
|
2009
|
|
S2 |
p. S61-
1 p.
|
artikel
|
| 86 |
The Changing Landscape of Secondary ITP: Introduction
|
Bussel, James B.
|
|
2009
|
|
S2 |
p. S1-
1 p.
|
artikel
|
| 87 |
The cytogenetic response as a surrogate marker of survival
|
Rosti, Gianantonio
|
|
2003
|
|
S2 |
p. 56-61
6 p.
|
artikel
|
| 88 |
The Expanding Role of Arsenic in Acute Promyelocytic Leukemia
|
Tallman, Martin S.
|
|
2008
|
|
S2 |
p. S25-S29
5 p.
|
artikel
|
| 89 |
Therapeutic Approaches to Secondary Immune Thrombocytopenic Purpura
|
Bussel, James B.
|
|
2009
|
|
S2 |
p. S44-S58
15 p.
|
artikel
|
| 90 |
Therapeutic Strategies for Hepatitis- and Other Infection-Related Immune Thrombocytopenias
|
Stasi, Roberto
|
|
2009
|
|
S2 |
p. S15-S25
11 p.
|
artikel
|
| 91 |
The role of metalloproteinases and adhesion molecules in interleukin-8-induced stem-cell mobilization
|
Fibbe, Willem E
|
|
2000
|
|
S2 |
p. 19-24
6 p.
|
artikel
|
| 92 |
The Role of Purine Analogues in Low-Intensity Regimens With Allogeneic Hematopoietic Stem Cell Transplantation
|
Foss, Francine M.
|
|
2006
|
|
S2 |
p. S35-S43
9 p.
|
artikel
|
| 93 |
Thrombocytopenia in Myelodysplastic Syndromes and Myelofibrosis
|
Boruchov, Adam M.
|
|
2009
|
|
S2 |
p. S37-S43
7 p.
|
artikel
|
| 94 |
Towards combination target-directed chemotherapy for chronic myeloid leukemia: Role of farnesyl transferase inhibitors
|
Daley, George Q.
|
|
2003
|
|
S2 |
p. 11-14
4 p.
|
artikel
|
| 95 |
Treatment of Follicular Non-Hodgkin's Lymphoma: The Old and the New
|
Friedberg, Jonathan W.
|
|
2008
|
|
S2 |
p. S2-S6
5 p.
|
artikel
|
| 96 |
Usefulness of quantitative assessment of Wilms tumor suppressor gene expression in chronic myeloid leukemia patients undergoing imatinib therapy
|
Cilloni, Daniela
|
|
2003
|
|
S2 |
p. 37-41
5 p.
|
artikel
|
Tijdschrift beschrijving